Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailEuropean National Society Cardiovascular Journals. Background, rationale and mission statement of the "Editors' Club" (Task Force of the European Society of Cardiology).
Alfonso, Fernando; Ambrosio, Giuseppe; Pinto, Fausto J. et al

in Acta Cardiologica (2008), 63(3), 281-7

Detailed reference viewed: 7 (0 ULg)
Full Text
See detailEuropean Nonproliferation Policy 1993-1995 - Chapitre consacré à la Belgique
Michel, Quentin ULg

in Müller, Harald (Ed.) European Nonproliferation Policy 1993-1995 (1996)

Detailed reference viewed: 3 (0 ULg)
Full Text
Peer Reviewed
See detailEuropean Organization for Research and Treatment of Cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer
Ardizzoni, A.; Manegold, C.; Debruyne, C. et al

in Clinical Cancer Research : An Official Journal of the American Association for Cancer Research (2003), 9(1), 143-150

Purpose: The purpose of this study was to assess the activity and toxicity of a combined regimen of topotecan and cisplatin in "sensitive" (s) and "refractory" (r) small-cell lung cancer (SCLC) patients ... [more ▼]

Purpose: The purpose of this study was to assess the activity and toxicity of a combined regimen of topotecan and cisplatin in "sensitive" (s) and "refractory" (r) small-cell lung cancer (SCLC) patients treated previously. Experimental Design: Patients with measurable SCLC and progressive disease after one first-line regimen were eligible for the study. Patients were enrolled in two separate groups: r group (patients who failed first-line treatment <3 months from treatment discontinuation) and s group (patients who responded to first-line treatment and progressed 2:3 months after treatment discontinuation). Cisplatin was given i.v. at the dose of 60 mg/m(2) on day 1, and topotecan was administered as a daily i.v. infusion at the dose of 0.75 mg/m(2) from day 1 to 5, every 3 weeks. Results: A total of 110 eligible (68 s and 42 r) patients were enrolled from 24 institutions. The main patient characteristics were as follows: median age 60 (s) and 55 (r) years, median performance status 1 for both (s) and (r). Seventy-four percent (s) and 67% (r) had extensive stage disease, including 22% and 36%, respectively, with brain metastases. A total of 398 chemotherapy courses were administered [median 4 (s) and 3 (r) per patient]. The most frequent and serious toxicity was myelosuppression. Grade IV neutropenia occurred in 62% (s) and 49% (r) of patients, with a 19% (s) and 15% (r) incidence of febrile neutropenia, and grade IV thrombocytopenia in 54% (s) and 44% (r). Most of these toxicities occurred during the first chemotherapy course and led to topotecan dose reduction and/or delay in the following courses. Grade III-IV nonhematological toxicity was uncommon. Five deaths possibly related to toxicity occurred among s patients only. Objective responses have been documented in 20 s patients, 19 partial responses and 1 complete response, (29.4% response rate; 95% confidence interval, 19-42), whereas, among r patients, 10 partial responses have been observed (23.8% response rate; 95% confidence interval, 12-39). Median survival for s and r was 6.4 and 6.1 months, respectively. Conclusions: The combination of cisplatin and topotecan, at this dose and schedule, shows activity and promising results in patients with refractory SCLC, with reversible myelosuppression being the main side effect. Additional development of this regimen, using better-tolerated schedules, is warranted in patients with refractory SCLC. [less ▲]

Detailed reference viewed: 17 (2 ULg)
Full Text
Peer Reviewed
See detailEuropean outbreak of atypical myopathy in the autumn 2009.
Van Galen, Gaby ULg; Amory, Hélène ULg; Busschers, Evita et al

in Journal of Veterinary Emergency & Critical Care (2010)

Background: Atypical myopathy (AM) is an acute, severe rhabdomyolysis occurring in grazing horses. Since In the beginning of October 2009, a new outbreak affects started in several European countries ... [more ▼]

Background: Atypical myopathy (AM) is an acute, severe rhabdomyolysis occurring in grazing horses. Since In the beginning of October 2009, a new outbreak affects started in several European countries. Geographic, demographic and clinical data of the reported cases in the month October 2009 are described. Key Findings: The survival rate over the month October 2009 was 25%. The most frequently observed clinical signs were congestedive mucous membranes, dyspnea, tachycardia, depression, weakness, stiffness, recumbency, trembling, transpirationsweating, and myoglobinuria. Non-survivors were significantly more often likely to be recumbent than survivors. Prognostic factors, symptomatic treatment and preventive measures are discussed. Significance: Slight differences were encountered during the described outbreak of AM in October 2009 compared to previous studies. Equine practitioners should be alert aware that previous epidemiological studies have shown that after a high prevalence this autumn, for new cases are likely to occur in the upcoming spring 2010. [less ▲]

Detailed reference viewed: 107 (15 ULg)
Full Text
Peer Reviewed
See detailEuropean outbreaks of atypical myopathy in grazing horses (2006-2009): Determination of indicators for risk and prognostic factors
Van Galen, Gaby ULg; Saegerman, Claude ULg; Marcilllaud Pitel, Christel et al

in Equine Veterinary Journal (2012), DOI: 10.1111/j.2042-3306.2012.00555.x

Appropriate management of atypical myopathy (AM) requires the establishment of an accurate diagnosis and prognosis. Furthermore, preventive measures to avoid AM need to be refined. The aims of the study ... [more ▼]

Appropriate management of atypical myopathy (AM) requires the establishment of an accurate diagnosis and prognosis. Furthermore, preventive measures to avoid AM need to be refined. The aims of the study were as follows: 1) to improve the diagnosis of AM; 2) to identify prognostic predictors; and 3) to refine recommended preventive measures based on indicators of risk factors. [less ▲]

Detailed reference viewed: 187 (14 ULg)
Full Text
Peer Reviewed
See detailThe European partnership with MERCOSUR: a Relationship based on Strategic and Neo-liberal principles
Santander, Sébastian ULg

in Journal of European Integration (2005), 27, 3

Since the early 1990s, the European Union has developed new instruments to consolidate its external action, especially in ‘low politics’. These new instruments include the signing of interregional ... [more ▼]

Since the early 1990s, the European Union has developed new instruments to consolidate its external action, especially in ‘low politics’. These new instruments include the signing of interregional arrangements with other regional groups. The EU’s region–to–region strategy towards the Common Market of the South (Mercosur) is in keeping with the latest trends of interregionalism. Since the birth of Mercosur, the EU has given technical, financial and diplomatic support to South America’s new regional- ism. The long–term goal is to conclude a region–to–region agreement in the political, cooperation and trade fields. By providing this support, the EU plays a role as an ‘exter- nal federator’ for new regional experiences through its interregionalist projects. Although ‘new interregionalism’ is a corollary of the new regionalism, interregionalism can contribute to the consolidation of regionalism. Moreover, by encouraging economic multilateralism, interregional arrangements can improve the governance of globalisation. [less ▲]

Detailed reference viewed: 89 (6 ULg)
Full Text
Peer Reviewed
See detailThe European Partnership with MERCOSUR: a Relationship Based on Strategic and Neoliberal Principles
Santander, Sébastian ULg

in Söderbaum, Frederik; Van Langenhove, Luk (Eds.) The EU as a Global Player: The Politics of Interregionalism (2006)

This article deals with the European Union’s Latin-American strategy and especially the relations that the European regional space has developed with the MERCOSUR since the early 1990s. The goal of the EU ... [more ▼]

This article deals with the European Union’s Latin-American strategy and especially the relations that the European regional space has developed with the MERCOSUR since the early 1990s. The goal of the EU is to conclude a bloc to bloc Association Agreement with the MERCOSUR which would cover both the political and cooperation aspects and which would include an ambitious free trade area for goods, services and investment. [less ▲]

Detailed reference viewed: 87 (7 ULg)
Full Text
Peer Reviewed
See detailA European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Ludwig, H.; Aapro, M.; Bokemeyer, C. et al

in Supportive Care in Cancer (in press)

Purpose – Patients with cancer frequently experience chemotherapy‐induced anaemia (CIA) and iron deficiency (ID). Erythropoiesis‐stimulating agents (ESA), iron supplementation and blood transfusions are ... [more ▼]

Purpose – Patients with cancer frequently experience chemotherapy‐induced anaemia (CIA) and iron deficiency (ID). Erythropoiesis‐stimulating agents (ESA), iron supplementation and blood transfusions are available therapies. This study evaluated routine practice in CIA management. Methods – Medical oncologists and/or haematologists from nine European countries (n=375) were surveyed on their last five cancer patients treated for CIA (n=1730). Information was collected on tests performed at diagnosis of anaemia, levels of haemoglobin (Hb), serum ferritin and transferrin saturation (TSAT), and applied anaemia therapies. Results – Diagnostic tests and therapies for CIA varied across Europe. Anaemia and iron status were mainly assessed by Hb (94%) and ferritin (48%) measurements. TSAT was only tested in 14%. At anaemia diagnosis, 74% of patients had Hb ≤10g/dL, including 15% with severe (Hb <8g/dL) anaemia. Low iron levels (ferritin ≤100ng/mL) were detected in 42% of evaluated patients. ESA was the most commonly used treatment (63%) and 30% of ESA‐treated patients also received iron supplementation. Most iron‐treated patients (74%) received an oral iron; intravenous iron was administered to 26%. 52% of patients received transfusions and in 76% of these, transfusions formed part of a regular anaemia treatment regimen. Management practices were similar in 2009 and 2011. Conclusion – Management of anaemia and iron status in patients treated for CIA varies substantially across Europe. Iron status is only assessed in half of the patients. In contrast to clinical evidence, iron treatment is underutilised and mainly based on oral iron supplementation. Implementation of guidelines needs to be increased, particularly the minimisation of blood transfusions. [less ▲]

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailEuropean perspectives on nurse education: system, aspirations and policy
Dury, Cécile ULg

Conference (2012, October)

The Conference: the Ninth International Guanghua Nursing Conference, and the first to be held outside China. The conference has been designed to maximise shared learning of nursings contribution to health ... [more ▼]

The Conference: the Ninth International Guanghua Nursing Conference, and the first to be held outside China. The conference has been designed to maximise shared learning of nursings contribution to health delivery, education and international collaboration. It provides a unique opportunity for international and national agencies, health policy and workforce analysts, regulators, universities, academics, academic and professional nurses and health professionals to contribute to analyses of nursing across continents. The conference will be of particular interest to Chinese, UK and European universities that have an interest in participating in the ambitious Guanghua Nurse Fund scheme to enhance nursing standards in China through engaging with European universities, a scheme which is a legacy of a Prime Ministers Initiative project funded by the British Council. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
See detailEuropean Perspectives on the Black Atlantic: Scientific Report
Cuder-Dominguez, Pilar; Ledent, Bénédicte ULg

Report (2007)

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailEuropean postmenopausal osteoporotic women have high prevalence of vitamin D inadequacy
Bruyère, Olivier ULg; Malaise, Olivier; Neuprez, Audrey ULg et al

in Arthritis and Rheumatism (2006, November), 54(Suppl), 585

Detailed reference viewed: 9 (0 ULg)
Full Text
See detailEuropean Private International Law : a Primer
Wautelet, Patrick ULg

Learning material (2011)

This presentation serves as background for a short seminar (12 h) taught each year at the Moscow State Institute of International Relations (MGIMO) which purports to give a general overview of the ... [more ▼]

This presentation serves as background for a short seminar (12 h) taught each year at the Moscow State Institute of International Relations (MGIMO) which purports to give a general overview of the achievements made so far in building a European private international law. The course is taught as part of the European law program offered by MGIMO's European Studies Institute which is co-sponsored by the College of Europe. Target audience of the course are Russian civil servants from different ministeries. [less ▲]

Detailed reference viewed: 81 (0 ULg)
Full Text
See detailEuropean project, demo “NETFLEX” For large integration of renewables using DLR, PST and PMU.
Lilien, Jean-Louis ULg

Conference (2012, February)

forecasting ampacity as a need for power system operation

Detailed reference viewed: 44 (7 ULg)
See detailEuropean psychological counselling in the 21st century will be multicultural or will not exist
Broonen, Jean-Paul ULg

in Van Esbroeck, Raoul; Butcher, Val; Broonen, Jean-Paul (Eds.) et al Decision Making for lifelong learning. Third Summer School. Proceedings (1997)

Detailed reference viewed: 13 (0 ULg)
See detailEuropean recommendations for the design of simple joints
Jaspart, Jean-Pierre ULg; Renkin, S.; Guillaume, M. L.

in European recommendations for the design of simple joints (2009)

Detailed reference viewed: 70 (0 ULg)
See detailEuropean registry for acromegaly
Beckers, Albert ULg

Scientific conference (2008, January 19)

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailEuropean regulatory perspectives for innovative therapies.
Ormarsdottir, S.; Reginster, Jean-Yves ULg; Abadie, Eric ULg

in Osteoporosis International (2008), 19(6), 725-31

The current regulatory requirements offer accelerated assessment of innovative therapies in Europe. Future perspectives include the need for increased interaction between stakeholders in pharmaceutical ... [more ▼]

The current regulatory requirements offer accelerated assessment of innovative therapies in Europe. Future perspectives include the need for increased interaction between stakeholders in pharmaceutical development. Development of new, high quality, effective and safe medicines in Europe is the common goal of academia, pharmaceutical industry and regulatory authorities. To achieve this, it is important that regulatory requirements do not hinder innovation and vice versa, innovation cannot be allowed to proceed without concerns for public health. Interaction between stakeholders in pharmaceutical development is of the utmost importance. A dialogue has begun and in the future it will be the responsibility of all stakeholders to ensure continuous exchanges in an environment that is characterised by new scientific advances and global development programmes. [less ▲]

Detailed reference viewed: 25 (7 ULg)
Full Text
Peer Reviewed
See detailEuropean Renal Best Practice Guideline on kidney donor and recipient evaluation and perioperative care
Abramowicz, Daniel; Cochat, Pierre; Claas, Frans H.J et al

in Nephrology Dialysis Transplantation (2014)

Detailed reference viewed: 30 (6 ULg)